Skip to main content
. 2017 Jul 6;17:79. doi: 10.1186/s12893-017-0274-2

Table 4.

Short-term (30-day) surgical outcome after one-stage and two-stage management

One-stage N = 97 One-stage N = 97 Two-stage N = 120 p- value total one-stage vs two-stage
TC approach N = 64 TD approach N = 33 Total
Successful CBD stone clearance, n (%)
 LC + LCBDE /Index ERCP a 59 (92.2) 27(81.8) 86 (88.7) 102 (85.0) 0.66
 After conversion to open surgery 3(4.7) 5 (15.2) 8 (8.2) 16 (13.3) 0.36
 After ERCP for residual stones 2 (3.1) 1 (3.0) 3 (3.1) 2 (1.7) 0.15
Total operative time, median (IQR) min b 140 (69.3) 165 (52.5) 150 (61.0) 112 (64.0) <0.001
30-d mortality, n (%) c 0 (0) 1 (3.0) 1 (1.0) 0 (0) 0.27
30-d overall morbidity, n(%) d 6 (9.4) 9 (27.2) 15 (15.5) 9 (7.5) 0.64
Surgical morbidity, n (%) 5(7.8) 4 (12.1) 9 (9.3) 5 (4.2) 0.13
 Bile leak 2 3 5 0
 Postoperative bleeding 1 0 1 2
 Wound infection 1 0 1 1
 Intra-abdominal abscess 0 1 1 0
 Post-ERCP pancreatitis 1 0 1 0
 Bleeding after ERCP 0 0 0 2
General morbidity, n (%) 1 (1.6) 5 (15.2) 6 (6.2) 5 (4.2) 0.50
 Renal insufficiency 0 1 1 0
 Fever, unknown origin 0 0 0 1
 Vocal cord injury from intubation 0 1 1 0
 Myocardial infarction 0 0 0 1
 Heart insufficiency 1 0 1 1
 Pneumonia 0 3 3 2
Dindo-Clavien gr IIIb-V, n (%) 2 (3.1) 3 (9.1) 5 (5.2) 2 (1.7) 0.25
Postoperative stay, median (IQR) days b 2 (1–3) 5 (2–8) 2 (2–5) 4.5 (3–7) <0.001
Reoperation, n (%) 2 (3.1) 2 (6.1) 4 (4.1) 1 (0.8) 0.11
Readmission, n(%) 3 (4.7) 16 (48.5) 19 (19.6) 7 (5.8) 0.002

TC transcystic, TD transductal

aTwo-stage group

bTwo-stage: ERCP and LC time

cClostridium perfringens sepsis

dFigures in the columns are not additive because some patients had more than one complication